Designing RNA medicines
mRNA and RNA therapeutics designed end to end — untranslated regions, codon choice, secondary structure, and stability — optimized for expression, durability, and delivery.
Center for AI-Designed Genetic and Cellular Encoding
A national center for AI-designed medicine
The future of gene and cell therapy is written in code — RNA code, genetic code, immune-recognition code, and cellular reprogramming code.
Gene and cell therapy is the proven frontier of medicine — mRNA reached billions, siRNA is an approved drug class, CAR-T delivers durable cures. The modality works. What's missing is the design substrate: a general way to design across the vast space of sequences, and a general way to predict who a therapy will work in. These are foundation-model problems — not solved one program at a time. CODE builds that substrate as a national center for the code of life.
mRNA and RNA therapeutics designed end to end — untranslated regions, codon choice, secondary structure, and stability — optimized for expression, durability, and delivery.
Regulatory elements, promoters, and gene circuits — plus the guides and edits that write durable, controllable function directly into the genome.
How T cells and antibodies recognize the body — antigens, epitopes, and TCR–pMHC binding — modeled and designed for precision immunotherapies and vaccines.
The transcription-factor programs that switch a cell's state — turning one cell type into another and tuning cells to repair, replace, and heal.
A design layer over the whole sequence space, a response layer that predicts who a therapy works in, and a closed loop that makes both better every cycle.
Language models of nucleotide sequence that read and generate DNA and RNA across the full design space — building on the DNABERT and GenomeOcean lineages.
An in-silico assay and in-silico patient that predict cellular response before the experiment — and group patients before the trial (Cell-JEPA lineage).
An active-learning agent designs, runs autonomous wet-lab experiments, reads them out, and chooses the next — generating sequence-to-function-to-response data no dataset holds, and improving every model each cycle.
Sample-efficient design of small interfering RNA, with knockdown and selectivity built in.
Joint generative design of coding sequence and UTRs for higher expression and durability — not stitched-together pipelines.
Engineered cell therapies designed end to end and matched to the patients most likely to respond.
In-silico cohorts so every therapy carries a hypothesis about who it helps — most failures are the wrong patient, not the wrong design.
Researchers, engineers, and partners across AI, RNA, genome, and cell engineering — at Northwestern and nationwide.
Get in touch